EICHORPublic-registry site landscape for NCT04461119, “Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia”, a Schizophrenia study sponsored by Newron Pharmaceuticals SPA. All data below is from public sources; Eichor is not affiliated with the sponsor.
| Trial | NCT04461119 (registry record) |
| Study title | Study to Determine the Safety, Tolerability, and Efficacy of Evenamide in Patients With Chronic Schizophrenia |
| Official title | A Phase II, Randomized, 4-Week, Double-Blind, Placebo-Controlled, Multiple-Dose Study, Designed to Determine the Safety, Tolerability, EEG Effects and Preliminary Efficacy of Fixed Oral Doses of 7.5 and 15 MG BID of Evenamide in Patients With Chronic Schizophrenia Who Are Symptomatic on Their Current Second-Generation Antipsychotic Medication |
| Sponsor | Newron Pharmaceuticals SPA |
| Condition(s) | Schizophrenia |
| Phase | PHASE2 |
| Listed sites | 14 |
| Site countries | United States, India |
Patient-friendly overview of this study: eichor.com/study/NCT04461119.
Eichor generates a preliminary site-risk snapshot for NCT04461119 — how the roster screens on competing-trial load, enrollment track record, and PI–indication fit — free, usually same day. Request it here →
Other Schizophrenia trials
← Eichor home · All tracked trials · Schizophrenia studies · Weekly briefs
